Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hormone-refractory prostate cancer: a multi-step and multi-event process.

A De La Taille1, F Vacherot, L Salomon

  • 1[1] Department of Urology, Hopital Henri Mondor, Créteil, France [2] Department of Urology, Columbia Presbyterian Medical Center, New York, USA.

Prostate Cancer and Prostatic Diseases
|December 24, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic value of comorbidities in older patients with cancer: the ELCAPA cohort study.

ESMO open·2023
Same author

[Early detection of prostate cancer: Towards a new paradigm?]

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
Same author

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
Same author

[High risk localized and locally advanced prostate cancer: Long-term oncological outcomes after prostatectomy].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2022
Same author

Robotic-assisted laparoscopy living donor nephrectomy: Technique and results of a monocentric retrospective series.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2022
Same author

[Assessment of positive surgical margins in the management of patients after radical prostatectomy for pT2 prostate cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2022

Prostate cancer cells often become resistant to androgen ablation therapy. This review explores the cellular pathways driving hormone-refractory prostate cancer (HRPC) development, moving beyond simple cell selection hypotheses.

Area of Science:

  • Oncology
  • Cell Biology
  • Urology

Background:

  • Prostate cancer growth historically depends on androgen stimulation.
  • Androgen ablation therapy is a primary treatment for metastatic prostate cancer.
  • Therapy resistance, leading to hormone-refractory prostate cancer (HRPC), is a significant clinical challenge.

Purpose of the Study:

  • To review and describe various cellular pathways contributing to the development of hormone-refractory prostate cancer.
  • To explore mechanisms beyond simple cell selection that explain androgen independence in prostate cancer.

Main Methods:

  • Literature review of studies on prostate cancer cell biology and androgen independence.
  • Analysis of proposed cellular mechanisms and genetic alterations in hormone-refractory prostate cancer.

Related Experiment Videos

Main Results:

  • Androgen independence in prostate cancer is a complex process, likely involving multiple steps and events.
  • Cellular mechanisms driving HRPC are not fully understood but involve pathways beyond initial androgen-dependent cell survival.
  • The selection hypothesis alone may not fully account for the development of HRPC.

Conclusions:

  • Hormone-refractory prostate cancer development is a multi-factorial process.
  • Understanding these diverse cellular pathways is crucial for developing new therapeutic strategies.
  • Further research is needed to elucidate the precise molecular mechanisms underlying androgen independence.